Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Stock Plunges By 25% After Setback
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.
